In a study reported in this issue of Neurology, Bolla et a1.l found that abstinent users of the recreational drug "Ecstasy" (methylenedioxymethamphetamine) have memory impairment. Moreover, the memory impairment correlated with the degree of drug exposure, and most importantly, with a reduction in brain serotonin, as indexed by CSF 5-hydroxyindoleacetic acid. The implications of this finding for public health are obvious, because the use of this drug is increasing steadily in college students and young adults. This study suggests that Ecstasy abusers risk serotonin neurotoxicity and permanent memory impairment. Clearly, additional research is necessary t o determine the exact mechanism of the neurotoxic effects of this drug and the long-term outcome of Ecstasy use in individuals.
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Neuropsychological studies of individuals who abuse Ecstasy should also address questions regarding the relation between the neurotransmitter serotonin and higher cognitive processes such as memory. Human cognitive neuroscientific research has emphasized identifying the neuroanatomic correlates of specific cognitive processes more than it has their neurochemical basis. Although the brain is clearly comprised of networks of interconnected regions that support cognitive function, these regions communicate via chemical messengers. Moreover, it is becoming clear that neurotransmitter systems in the brain are highly organized and highly specific. It should be possible, and it is important, to determine the neurochemical substrates of cognitive processes. Such research will both advance our understanding of normal brain function and assist us in developing rational therapies for patients with cognitive disorders.
Investigations of the link between neurotransmitters and cognitive processes are difficult because disorders of isolated deficits in a single neurotransmitter system are uncommon. PD, as one example, has greatly advanced our knowledge of the relation between the neurotransmitter dopamine and cognitive function. In addition, abundant evidence from study of monkeys has led to the finding that dopamine plays a critical role in short-term (or working) memory-a function thought to be subserved by the prefrontal cortex. For example, in monkeys, depletion of dopamine in the prefrontal cortex, or pharmacologic blockade of dopamine receptors, induces impairment in spatial working memory tasks. Furthermore, dopaminergic agonists administered to those same monkeys can reverse their delayedresponse impairment.2 Expanding on these findings in humans, the dopaminergic agonist bromocriptine has been shown to improve performance on working memory tasks when given to normal young volunt e e r~,~ as well as to patients with frontal lobe i n j~r y .~ In contrast to dopamine, acetylcholine appears to be linked to long-term memory. Early studies observed that healthy young volunteers developed impairment of immediate and delayed free recall of word lists following the administration of the anticholinergic preparation ~copolamine.~ Furthermore, anticholinergics impair episodic long-term memory only, leaving semantic, procedural, and working memory intact.6 These observations have led to numerous investigations of acetylcholine replacement and augmentation therapy as a means of improving memory function in patients with AD, in which a dominant cognitive impairment is amnesia and an acetylcholine deficiency exists.
Serotonin, however, is a neurotransmitter about which little is known concerning its role in memory or other cognitive processes. In the few studies that have been performed that assessed the effect of serotonin agonists and antagonists, no unified theory has emerged.7 The study of Bolla et a1.l of Ecstasy abusers was not designed to determine the role of serotonin in specific components of memory. The subjects in the study were tested on tasks of long-term memory but not on tasks that probe other components of memory such as working memory (except for digit and visual span), semantic memory, or procedural memory. In addition, a link between long-term memory and serotonin cannot be firmly established from this study because the subjects were not tested extensively on other cognitive measures to determine how specific the cognitive deficit was to memory. Therefore, it remains possible that the memory deficit was secondary to impairment in other cognitive domains, such as high-level attention or executive function. More comprehensive cognitive testing in Ecstasy abusers could provide information regarding the underlying neural systems that may be affected by serotonin toxicity. Nevertheless, this study provides the first glimpse into the relation of serotonin and memory in humans, and additional investigation of Ecstasy abusers could provide a useful model for providing invaluable neuroscientific information about the neurochemistry of cognition.
Memory is not a unitary system, and the many different component memory processes are likely influenced by different neurotransmitters. Thus, goals for research in developing pharmacologic therapies for improving memory function should be twofold. First, to develop therapies for isolated memory deficits (i.e., working memory impairment from a closed head injury), it is critical to establish the links between individual neurotransmitters and wellcharacterized component processes of memory. Second, to develop therapies for global memory impairment, such as that found in patients with AD, it is critical to develop innovative clinical trials that use combinations of drugs that influence several neurotransmitter systems. For example, in rats, there is a high concentration of y-aminobutyric (GABA) receptors in the basal forebrain, and GABA antagonists (i.e., benzodiazepines) cause a decrease in acetylcholine release, and cause memory impairment. In contrast, GABA agonists reverse the memory-impairing effects of anticholinergk8 Thus, a combination of a GABA and a cholinergic agonist could be more beneficial in treating a cholinergic deficiency than either alone. To my knowledge, clinical trials using combinations of different neurotransmitters have not been performed.
